264
Participants
Start Date
June 30, 2006
Primary Completion Date
October 31, 2007
Study Completion Date
October 31, 2007
Lofexidine
Lofexidine is an alpha2-adrenergic-agonist with mild to moderate antihypertensive actions. It is mainly used in the alleviation of opioid withdrawal signs and symptoms.
Placebo
Placebo is an exact match of lofexidine, less the active ingredient.
Richmond Medical Center, Staten Island
VA Medical Center, Philadelphia, Philadelphia
CNS Psychiatric Institute of Washington, Washington D.C.
VA Maryland Health Care System, Baltimore, Baltimore
Atlanta Center for Medical Research, Atlanta
University of Kentucky, Lexington
Wayne State University School of Medicine, Detroit
Aurora Psychiatric Hospital, Wauwatosa
Alexian Center for Psychiatric Research, Hoffman Estates
Research Across America, Dallas
VA Salt Lake City Health Care System, Salt Lake City, Salt Lake City
CNS, Cerritos, Cerritos
VA Puget Sound Health Care System, Seattle, Seattle
VA Medical Center, Providence, Providence
Psychiatric Hospital at Vanderbilt, Nashville
University of Texas Health Science Center at San Antonio, San Antonio
National Institute on Drug Abuse (NIDA)
NIH
USWM, LLC (dba US WorldMeds)
INDUSTRY
US Department of Veterans Affairs
FED